General Report Contents
• Market Analyses include: Unit Sales, ASPs, Market Value & Growth Trends
• Market Drivers & Limiters for each chapter segment
• Competitive Analysis for each chapter segment
• Section on recent mergers & acquisitions
Orthopedic biomaterials are associated with high research and development (R&D) costs, which have subsequently led to premium pricing to recoup these initial costs. This is the case for competitors in the cellular allograft, cell therapy and growth factor segments of the U.S. orthopedic biomaterials market. In particular, orthopedic growth factors have had relatively high average selling prices (ASP) since their introduction to the market due to the high costs of recombinant growth factor technologies. The high R&D costs associated with the growth factor segment provide entry barriers against potential competitors. Currently there are only two growth factor BMP-2 products in the United States. Since they’re both used in different indications, there is a lack of direct competition, allowing companies such as Medtronic to charge a premium for the Spine indication and recover the large initial costs associated with R&D. The commoditized nature in some parts of the market, such as the allograft and DBM segments, which is due to the lack of product differentiation, has limited growth. The market is being driven by more competitors venturing outside their traditional space to tap into the high growth segments where they can charge a premium. These segments may include the cell therapy and cellular allograft segments, both of which have relatively high ASP.
'
TABLE OF CONTENTS I
LIST OF FIGURES XVII
LIST OF CHARTS XVIII
EXECUTIVE SUMMARY 1
U.S. ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 1
COMPETITIVE ANALYSIS 4
MARKET TRENDS 6
MARKET DEVELOPMENTS 8
PROCEDURE NUMBERS 9
MARKETS INCLUDED 11
KEY REPORT UPDATES 13
VERSION HISTORY 13
RESEARCH METHODOLOGY 14
1.1 RESEARCH SCOPE 14
1.2 IDATA’S 9-STEP METHODOLOGY 14
Step 1: Project Initiation & Team Selection 14
Step 2: Prepare Data Systems and Perform Secondary Research 16
Step 3: Preparation for Interviews & Questionnaire Design 17
Step 4: Performing Primary Research 18
Step 5: Research Analysis: Establishing Baseline Estimates 20
Step 6: Market Forecast and Analysis 21
Step 7: Identify Strategic Opportunities 23
Step 8: Final Review and Market Release 24
Step 9: Customer Feedback and Market Monitoring 25
DISEASE OVERVIEW 26
2.1 BASIC ANATOMY 26
2.1.1 Osteology and Musculoskeletal System 26
2.2 DISEASE PATHOLOGY AND DISORDERS 28
2.2.1 General Diagnostic 28
2.2.2 Osteoporosis 29
2.2.3 Osteoarthritis 29
2.2.4 Indication for Bone Graft Procedure 30
2.2.5 Indication for Cartilage Repair 31
2.2.6 Degenerative Disc Disease 32
2.3 PATIENT DEMOGRAPHICS 34
2.3.1 General Statistics 34
PROCEDURE NUMBERS 36
3.1 PROCEDURE DEFINITIONS 36
3.2 BONE GRAFT PROCEDURE NUMBERS BY TYPE 37
3.3 BONE GRAFT SUBSTITUTE PROCEDURE NUMBERS 40
3.3.1 By Material 40
3.3.2 By Indication 43
3.4 GROWTH FACTOR BONE GRAFT PROCEDURE NUMBERS 47
3.5 CELLULAR ALLOGRAFT PROCEDURE NUMBERS 49
3.6 CELL THERAPY TREATMENT NUMBERS 51
3.6.1 Platelet-Rich Treatment Numbers by Indication 53
3.6.2 Bone Marrow Concentrate Treatment Numbers by Indication 55
3.7 HYALURONIC ACID TREATMENT NUMBERS BY TYPE 57
3.8 CARTILAGE REPAIR PROCEDURE NUMBERS BY TYPE 60
3.9 SPINAL MACHINED BONE ALLOGRAFT PROCEDURE NUMBERS BY APPROACH 63
ABBREVIATIONS 65
APPENDIX II: COMPANY PRESS RELEASES 67
Chart 1 1: Orthopedic Biomaterials Market by Segment, U.S., 2013 – 2023 3
Chart 1 2: Orthopedic Biomaterials Market Overview, U.S., 2016 & 2023 3
Chart 3 1: Bone Graft Procedure Numbers by Type, U.S., 2013 – 2023 39
Chart 3 2: Bone Graft Substitute Procedure Numbers by Material, U.S., 2013 – 2023 42
Chart 3 3: Bone Graft Substitute Procedure Numbers by Indication, U.S., 2013 – 2023 46
Chart 3 4: Growth Factor Bone Graft Procedure Numbers, U.S., 2013 – 2023 48
Chart 3 5: Cellular Allograft Procedure Numbers, U.S., 2013 – 2023 50
Chart 3 6: Cell Therapy Treatment Numbers by Type, U.S., 2013 – 2023 52
Chart 3 7: Platelet-Rich Plasma Treatment Numbers by Indication, U.S., 2013 – 2023 54
Chart 3 8: Bone Marrow Concentrate Treatment Numbers by Indication, U.S., 2013 – 2023 56
Chart 3 9: Hyaluronic Acid Treatment Numbers by Type, U.S., 2013 – 2023 59
Chart 3 10: Cartilage Repair Procedure Numbers by Type, U.S., 2013 – 2023 62
Chart 3 11: Spinal Machined Bone Allograft Procedure Numbers by Approach, U.S., 2013 – 2023 64
Figure 1 1: Orthopedic Biomaterials Market Share Ranking by Segment, U.S., 2016 (1 of 2) 4
Figure 1 2: Orthopedic Biomaterials Market Share Ranking by Segment, U.S., 2016 (2 of 2) 4
Figure 1 3: Companies Researched in this Report, U.S., 2016 5
Figure 1 4: Factors Impacting the Orthopedic Biomaterials Market by Segment, U.S. (1 of 2) 6
Figure 1 5: Factors Impacting the Orthopedic Biomaterials Market by Segment, U.S. (2 of 2) 7
Figure 1 6: Recent Events in the Orthopedic Biomaterials Market, U.S., 2013 – 2016 8
Figure 1 7: Orthopedic Biomaterials Markets Covered, U.S., 2016 (1 of 2) 9
Figure 1 8: Orthopedic Biomaterials Markets Covered, U.S., 2016 (2 of 2) 10
Figure 1 9: Orthopedic Biomaterials Markets Covered, U.S., 2016(1 of 3) 11
Figure 3 1: Bone Graft Procedure Numbers by Type, U.S., 2013 – 2023 38
Figure 3 2: Bone Graft Substitute Procedure Numbers by Material, U.S., 2013 – 2023 41
Figure 3 3: Bone Graft Substitute Procedure Numbers by Indication, U.S., 2013 – 2023 (1 of 2) 44
Figure 3 4: Bone Graft Substitute Procedure Numbers by Indication, U.S., 2013 – 2023 (2 of 2) 45
Figure 3 5: Growth Factor Bone Graft Procedure Numbers, U.S., 2013 – 2023 47
Figure 3 6: Cellular Allograft Procedure Numbers, U.S., 2013 – 2023 49
Figure 3 7: Cell Therapy Treatment Numbers by Type, U.S., 2013 – 2023 51
Figure 3 8: Platelet-Rich Plasma Treatment Numbers by Indication, U.S., 2013 – 2023 53
Figure 3 9: Bone Marrow Concentrate Treatment Numbers by Indication, U.S., 2013 – 2023 55
Figure 3 10: Hyaluronic Acid Treatment Numbers by Type, U.S., 2013 – 2023 58
Figure 3 11: Cartilage Repair Procedure Numbers by Type, U.S., 2013 – 2023 61
Figure 3 12: Spinal Machined Bone Allograft Procedure Numbers by Approach, U.S., 2013 – 2023 63
Figure 5 1: Press Release Summary 67
MedtronicGenzymeDePuy SynthesAnika TherapeuticsFerring PharmaceuticalsStrykerNuVasiveBioventusZimmer BiometIntegra LifeSciencesRTI SurgicalFidia PharmaceuticalsMTFOrthofixArthrexAlloSourceAastromBaxterHarvest TechnologiesWright MedicalBacterin InternationalArteriocyteExactechLifeNet HealthBiocompositesAlphatec SpineCelling BiosciencesGlobus MedicalNuo TherapeuticsK2M*Not all companies are currently active in every segment or sub-report from this suite. For more details contact an iData Research Product Advisor.
